18.55% in phase 3. The only approved dual GLP-1/glucagon agonist in the world, and almost nobody outside China has heard of it.
Mazdutide (IBI362) is a once-weekly GLP-1/glucagon dual agonist. China approved it for weight management. The GLORY-2 phase 3 trial reported 18.55% mean weight loss at 60 weeks on 9 mg weekly. That puts it ahead of semaglutide, behind tirzepatide, and makes it the most proven glucagon-containing compound you can actually read phase 3 data for.
| Trial | Design | Dose | Result |
|---|---|---|---|
| GLORY-2 (phase 3) | 60 weeks | 9 mg weekly | 18.55% |
| GLORY-1 (phase 3) | 48 weeks | 4 mg / 6 mg weekly | Phase 3 completed |
Every glucagon-containing obesity drug is a bet that the field is watching. Retatrutide and survodutide are still investigational. Mazdutide already cleared phase 3 twice and won approval. That makes its data the best available preview of whether the glucagon strategy works at scale. So far, the answer looks like yes.
The Western blind spot is an information problem, not a science problem. English-language coverage of the GLORY trials has been thin, which is exactly why this page exists.
Yes, in China. Mazdutide (IBI362) was approved by China's NMPA for weight management. It is not approved in the US, Canada, or Europe.
Mazdutide pairs GLP-1 with glucagon instead of GIP. Its 18.55% (GLORY-2, 60 weeks) sits below tirzepatide's 20.9% (SURMOUNT-1, 72 weeks) but above semaglutide's 14.9%. Cross-trial comparisons are directional only.
Glucagon raises energy expenditure. The idea is the same one behind retatrutide and survodutide: burn more while eating less. The GLP-1 component offsets glucagon's blood-sugar risk.
It was developed in China (Innovent/Lilly partnership) and approved there first. Western coverage has been thin, which is why honest English-language breakdowns are hard to find.
All compounds are sold strictly as laboratory research chemicals, not for human consumption. Trial figures are mean changes in the cited trial populations.
